{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-31365765-lixisenatide:v1","objectPathId":"pubmed-pmid-31365765-lixisenatide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-31365765-lixisenatide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-31365765-lixisenatide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-31365765-lixisenatide-v1.md"},"story":{"slug":"pubmed-pmid-31365765-lixisenatide","version":1,"domain":"Literature metadata","dateInSource":"2026-01-27","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["lixisenatide"],"peptides":[{"slug":"lixisenatide","url":"https://peptidescanner.com/peptides/lixisenatide/"}]},"claims":[{"id":"headline","text":"Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.","sourceIds":["pubmed-observation-pmid-31365765-2026-01-27-e6483945acba"]},{"id":"summary","text":"PubMed lists PMID 31365765 in Diabetic medicine : a journal of the British Diabetic Association as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-31365765-2026-01-27-e6483945acba"]},{"id":"paragraph-1","text":"PubMed lists PMID 31365765 in Diabetic medicine : a journal of the British Diabetic Association as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-31365765-2026-01-27-e6483945acba"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-31365765-2026-01-27-e6483945acba"]}],"sources":[{"id":"pubmed-observation-pmid-31365765-2026-01-27-e6483945acba","name":"PubMed","sourceClass":"A","title":"Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. · retained source version 1:2026-01-27:current:e6483945acbafb19aa5e8c24d72ca0995c20517316e4b93de46074aea7dc722a","url":"https://pubmed.ncbi.nlm.nih.gov/31365765/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"5ffd169b97cf9e76fc89863361411dc0a07f38441db870a3666305cc268260f7","tierARecordSha256":"f42c7ce29153ec1e35be67bec58c8d197c285d93db858baa8f70f46e5e42ac77"},"integrity":{"algorithm":"sha256","contentSha256":"8afab0d60556221eba2cc078dc24b6fd5e1513cab0e60ec9bba0d9fec5824c17"}}